Endoscopic stenting for malignant biliary obstruction: results of a nationwide experience

Simple item page
dc.contributor.authorLubbe, Jeanneen_ZA
dc.contributor.authorSandblom, Gabrielen_ZA
dc.contributor.authorArnelo, Urbanen_ZA
dc.contributor.authorJonas, Eduarden_ZA
dc.contributor.authorEnochsson, Larsen_ZA
dc.date.accessioned2023-05-10T09:58:29Zen_ZA
dc.date.available2023-05-10T09:58:29Zen_ZA
dc.date.issued2021-05en_ZA
dc.descriptionCITATION: Lubbe, J. et al 2021. Endoscopic Stenting for Malignant Biliary Obstruction: Results of a Nationwide Experience. Clinical Endoscopy 54(2021):713-721 pages. doi.10.5946/ce.2021.016en_ZA
dc.descriptionThe original publication is available at: e-ce.orgen_ZA
dc.description.abstractBackground/Aims: Many unanswered questions remain about the treatment of malignant hilar obstruction. We investigated endoscopic stenting for malignant biliary strictures, as reported in a nationwide registry. Methods: All endoscopic retrograde cholangiopancreatography (ERCP) procedures entered in the Swedish Registry of Gallstone Surgery and ERCP from January 2010 to December 2017 in which stenting was performed for malignant biliary stricture management were included in this study. Patency was estimated by determining the time to reintervention. Results: Endoscopic stenting was performed for malignant stricture management in 4623 ERCP procedures, of which 1364 (29.5%) were performed for hilar strictures. Of the hilar strictures, 320 (23.5%) were intrahepatic strictures (Bismuth–Corlette III– IV). Adverse events were more common after hilar stenting than after distal stenting (17.2% vs. 12.0%, p<0.0001). The 6-month reintervention rate was 73.4% after hilar stenting compared with 55.9% after distal stenting (p<0.0001). The 6-month reintervention rates for Bismuth–Corlette types I, II, IIIa, IIIb, and IV were 70.4%, 75.6%, 90.0%, 87.5%, and 85.7%, respectively. In multivariate analysis, the risk for reintervention was three times higher after hilar stenting than after distal stenting (hazard ratio 3.47, 95% confidence interval 2.01–6.00, p<0.001). Conclusions: This study with a relatively large patient cohort undergoing endoscopic stenting confirms that stenting for malignant hilar obstruction has more adverse events and lower patency than stenting for distal malignant obstruction. Clin Endosc 2021;54:713-721en_ZA
dc.description.versionPublisher’s versionen_ZA
dc.format.extent9 pagesen_ZA
dc.identifier.citationLubbe, J. et al 2021. Endoscopic Stenting for Malignant Biliary Obstruction: Results of a Nationwide Experience. Clinical Endoscopy 54(2021):713-721 pages. doi.10.5946/ce.2021.016en_ZA
dc.identifier.issn2234-2400 (print)en_ZA
dc.identifier.issn2234-2443 (online)en_ZA
dc.identifier.otherdoi.10.5946/ce.2021.016en_ZA
dc.identifier.urihttp://hdl.handle.net/10019.1/126888en_ZA
dc.language.isoen_ZAen_ZA
dc.publisherKorean Society of Gastrointestinal Endoscopyen_ZA
dc.rights.holderAuthors retain copyrighten_ZA
dc.subjectEndoscopic retrograde cholangiopancreatographyen_ZA
dc.subjectEndoscopic surgeryen_ZA
dc.subjectBile ducts -- Obstructionsen_ZA
dc.titleEndoscopic stenting for malignant biliary obstruction: results of a nationwide experienceen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
jeanne_endoscopic_2021.pdf
Size:
501.86 KB
Format:
Adobe Portable Document Format
Description:
download article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles (Surgery)